Montefiore in the News
Patients’ Own Immune Cells May Hold The Key To Fighting Deadly Cancers
Montefiore and New York Blood Center Partnership Holds Promise for People Suffering from Advanced Cancers
NEW YORK (December 14, 2017) – Scientists have taken a significant step forward in efforts to harness our own white blood cells to fight deadly cancers. A pilot study, funded by Montefiore Einstein Center for Cancer Care, in partnership with New York Blood Center (NYBC), has successfully demonstrated that white blood cells can be removed, genetically modified and reinserted into cancer patients. This holds potential to fight cancers that standard therapy has failed to treat. The next step is to duplicate this finding in multiple patients.
Montefiore holds the investigational new drug application from the FDA to test the safety and feasibility of the therapy. Working with the National Cancer Institute-designated Albert Einstein Cancer Center, the trial kicked off this summer.
The goal of the pilot study is to enroll five patients and confirm the feasibility, and safety of the therapy for solid tumors, such as breast cancer, sarcomas and lung cancer.
Eligibility for the trial requires highly specific criteria:
- A hereditary marker, found in only 20 percent of Montefiore’s patient population
- Tumors expressing the NY ESO-1 protein, which is found in 30 percent of all solid tumors
- Advanced metastatic cancer which has failed to respond to standard therapy
It’s all about the blood, so NYBC plays a critical role:
“We isolate a person’s blood cells and grow them in the lab with a virus that inserts new DNA into the blood cells,” says Amanda Marchiando, PhD, MPH, Cellular Therapy & Regenerative Medicine Scientist at New York Blood Center. “This reprograms the cells to recognize the NY ESO-1 protein on a patient’s tumors and attack it.”
Once newly engineered cells are created in the NYBC, patients’ bodies will be prepared for a cell transfusion. This will include one week of chemotherapy at Montefiore to wipe out many of the remaining white blood cells. The clean slate allows the new and improved cells, which are delivered through an IV-bag in 20 minutes, to become the first in line to attack the cancer. Immunotherapy is also given to make the re-engineered cells even stronger.
“We are optimistic that this therapy could become a viable option for people with cancer who are running out of options,” says principal investigator Ira Braunschweig, M.D., director, Stem Cell Transplantation and clinical program director, Hematologic Malignancies, Montefiore Einstein Center for Cancer Care, Associate Professor, Department of Medicine, Einstein.
This scientific development builds off the research of Dr. Steven Rosenberg of the National Cancer Institute.
“Though the main goal of the phase one pilot study is making sure the treatment is safe, we always hope that our patients will be better than they were before they walked through our doors,” says Katia Papalezova, M.D., surgical oncologist, Department of Surgery and director, Melanoma and Soft Tissue Tumors, co-director, IL-2 program, Montefiore Einstein Center for Cancer Care and Associate Professor of Surgery, Einstein, one of the lead clinical investigators. “It is gratifying to be on the frontlines of scientific research that has the potential to help so many people.”